BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates

Reuters11-12

Nov 12 (Reuters) - Metagenomi Inc MGX.O:

METAGENOMI INC -MGX-001 DEMONSTRATED CURATIVE FVIII ACTIVITY IN NON-HUMAN PRIMATES
METAGENOMI: PRE-IND REGULATORY MEETING EXPECTED IN Q4 2025 WITH IND & CLINICAL TRIAL APPLICATION SUBMISSIONS EXPECTED IN 4Q 2026

Source text: ID:nGNX3Qp3Pr

Further company coverage: MGX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582882318?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 05:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582882318","market":"us","top_or_hot":-1,"title":"BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates</title></head><body><p><span>Nov 12 (Reuters)</span><span> - </span>Metagenomi Inc <span>MGX.O</span>:</p><ul><li><p>METAGENOMI INC -MGX-001 DEMONSTRATED CURATIVE FVIII ACTIVITY IN NON-HUMAN PRIMATES</p></li><li><p>METAGENOMI: PRE-IND REGULATORY MEETING EXPECTED IN Q4 2025 WITH IND &amp; CLINICAL TRIAL APPLICATION SUBMISSIONS EXPECTED IN 4Q 2026</p></li></ul><p>Source text: <span>ID:nGNX3Qp3Pr</span></p><p>Further company coverage: <span>MGX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 05:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates</title></head><body><p><span>Nov 12 (Reuters)</span><span> - </span>Metagenomi Inc <span>MGX.O</span>:</p><ul><li><p>METAGENOMI INC -MGX-001 DEMONSTRATED CURATIVE FVIII ACTIVITY IN NON-HUMAN PRIMATES</p></li><li><p>METAGENOMI: PRE-IND REGULATORY MEETING EXPECTED IN Q4 2025 WITH IND &amp; CLINICAL TRIAL APPLICATION SUBMISSIONS EXPECTED IN 4Q 2026</p></li></ul><p>Source text: <span>ID:nGNX3Qp3Pr</span></p><p>Further company coverage: <span>MGX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MGX","symbol_name":"Metagenomi Technologies, LLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nFWN3WN1H5:1","article_id":"2582882318","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582882318","pubTimestamp":1762898364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human PrimatesNov 12 (Reuters) - Metagenomi Inc MGX.O:METAGENOMI INC -MGX-001 DEMONSTRATED CURATIVE FVIII ACTIVITY IN NON-HUM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MGX":"Metagenomi Technologies, LLC","BK4139":"生物科技"},"translate_title":"Brief-Metagenomi Inc-MGX-001在非人灵长类动物中证明了FVIII治疗活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGX":0.9},"content_text":"BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human PrimatesNov 12 (Reuters) - Metagenomi Inc MGX.O:METAGENOMI INC -MGX-001 DEMONSTRATED CURATIVE FVIII ACTIVITY IN NON-HUMAN PRIMATESMETAGENOMI: PRE-IND REGULATORY MEETING EXPECTED IN Q4 2025 WITH IND & CLINICAL TRIAL APPLICATION SUBMISSIONS EXPECTED IN 4Q 2026Source text: ID:nGNX3Qp3PrFurther company coverage: MGX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582882318","isCrawlerRequest":true}